including neurologists and psychiatrists, and to seek strategic collaborations with other pharmaceutical companies to license our products outside the United States.We use our proprietary technologies to enhance the therapeutic benefits of approved drugs through advanced extended release formulations.
any of our other product candidates by the FDA or other regulatory authorities may be delayed, limited, or denied, any of which would adversely affect our ability to generate operating revenues.•We are dependent on the successful
prospectus.Year Ended December 31,Nine Months EndedSeptember 30,20092010201120112012(unaudited)(in thousands, except share and per share information)Consolidated Statement of Operations Data:RevenuesDevelopment and milestone revenues$1,050$106$803$761$391Royalty revenues36,875————Total revenues37,925106803761391Costs and expensesResearch and development29,26035,14930,62723,12618,367Selling, general and administrative4,6495,0807,9285,14311,450Total costs and expenses33,90940,22938,55528,26929,817Operating income (loss) from continuing operations4,016(40,123)(37,752)(27,508)(29,426)Other income (expense):Interest income122107312991Interest expense——(1,866)(1,357)(2,771)Other—54211730(665)Total other income (expense)122649(1,718)(1,298)(3,345)Income (loss) from continuing operations before income taxes4,138(39,474)(39,470)(28,806)(32,771)Income tax benefit—39916,245——Income (loss) from continuing operations4,138(39,075)(23,225)(28,806)(32,771)Discontinued operations:Income (loss) from discontinued operations, net of tax(3,678)6122,188646—Gain on disposal of discontinued operations, net of tax——74,852——Income (loss) from discontinued operations(3,678)61277,040646—Net income (loss)$460$(38,463)$53,815$(28,160)$(32,771)Cumulative dividends on Series A convertible preferred stock$(3,430)$(3,430)(3,430)(2,573)(1,143)Net income (loss) attributable to common stockholders$(2,970)$(41,893)$50,385$(30,733)$(33,914)8Table of ContentsYear Ended December 31,Nine Months EndedSeptember 30,20092010201120112012(unaudited)(in thousands, except share and per share information)Income (loss) per common shareBasicContinuing operations$0.50$(26.77)$(16.60)(19.68)(2.36)Discontinued operations(2.60)0.3947.990.40—Net income (loss)(2.10)(26.38)31.39(19.28)(2.36)DilutedContinuing operations$0.29$(26.77)$(16.60)(19.68)(2.36)Discontinued operations(0.26)0.3947.990.40—Net income (loss)0.03(26.38)31.39(19.28)(2.36)Weighted average number of common sharesBasic1,413,3741,587,9681,605,3241,594,28814,356,546Diluted14,081,1861,587,9681,605,3241,594,28814,356,546The pro forma balance sheet data set forth below gives effect to the issuance and sale of 6,000,000 shares of our common stock in this offering at the assumed
In this event, the market price of our common stock may decline and you could lose part or all of your investment.Risks Related to Our Business and IndustryWe are dependent on the commercial success of Oxtellar XR and Trokendi XR which may never be successfully commercialized.To date, we have expended significant time, resources, and effort on the development of Oxtellar XR and Trokendi XR, and a substantial majority of
collaboration partners fail to effectively perform under our arrangements for any reason, we may not be able to find a suitable replacement partner on a timely basis or on acceptable terms.Adoption of Oxtellar XR or Trokendi XR may be slow or limited for a variety of reasons including competing branded and generic therapies or safety issues.
systems and personnel appropriately and successfully in order to achieve our commercialization plans for Oxtellar XR and Trokendi XR, our revenues could suffer and our business could be harmed.We are dependent on the success of our product candidates, which may never receive regulatory approval or be successfully commercialized.To date, we have expended significant time, resources, and effort on the development of our product candidates, and a substantial majority of our
development costs could substantially increase and our business, financial condition and results of operations will be adversely affected.We have limited sales and marketing experience and resources, and we may not be able to effectively market and sell our products or product candidates, if approved, in the
force capability may not be justifiable in light of the revenues generated by Oxtellar XR, Trokendi XR if it receives final approval, or any of our product candidates if approved by the FDA; and•our direct sales and marketing efforts may not be
we are unable to establish adequate sales and marketing capabilities or are unable to do so in a timely manner, we may not be able to generate product revenues and may never become profitable.The commercial success of our products and product candidates, if approved, depends upon attaining market acceptance by physicians, patients, third-party payors and the
Oxtellar XR and Trokendi XR are not NCEs, if commercially launched, they would be subject to the risk that they will not be able to gain significant market share against existing AEDs. If our products or product candidates do not achieve an adequate level of acceptance by physicians, third-party payors and patients, we may not generate sufficient revenues from these products or
adversely affect our ability to generate operating revenues.Our business depends on the successful development and commercialization of our products and product candidates.
to generate revenues, and any failure to obtain such approval for all of the indications and labeling claims we deem desirable could reduce our potential revenues.Our trials may fail to demonstrate acceptable levels of safety, efficacy or any other requirements of our product candidates, which could prevent or significantly delay
in connection with the development of or realize revenues from Oxtellar XR or Trokendi XR.If we do not obtain marketing exclusivity for our product candidates, our business may suffer.Under the Hatch-Waxman Amendments, three years of marketing exclusivity may be granted for the approval of new and supplemental NDAs, including
trial operations or trial sites by the FDA or other regulatory authorities that ultimately result in the imposition of a clinical hold;•unforeseen safety issues; or•lack of adequate funding to continue the trial.In addition, failure to conduct the clinical trial in accordance with regulatory requirements or the trial protocols may also result in the inability to use the data to support product approval.
Competition may increase further as a result of advances made in the commercial applicability of technologies and greater availability of capital for investment.19Table of ContentsOur products and our product candidates, if they receive regulatory approval, may be subject to restrictions or withdrawal from the market and we may be subject to penalties
third-party collaborators to successfully market and commercialize our product candidates outside of the United States would diminish our revenues and harm our results of operations.Limitations on our patent rights relating to our product candidates may limit our ability to prevent third parties from competing against us.Our success will depend on our ability to obtain and maintain patent protection for our proprietary technologies and our product candidates, preserve
material adverse effect on our business.Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell their approved products
sufficient financial resources or capabilities to continue development and commercialization of the product candidate on our own, which could adversely affect our results of operations.We rely and will continue to rely on outsourcing arrangements for certain of our activities, including clinical research of our product candidates and manufacturing of our
any product candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and applicable foreign